Spectral  ||| S:0 E:9 ||| NNP
Analysis  ||| S:9 E:18 ||| NNP
about  ||| S:18 E:24 ||| IN
the  ||| S:24 E:28 ||| DT
Pharmaceutical  ||| S:28 E:43 ||| NNP
Cocrystal  ||| S:43 E:53 ||| NNP
Formation  ||| S:53 E:63 ||| NNP
of  ||| S:63 E:66 ||| IN
Piracetam  ||| S:66 E:76 ||| NNP
and  ||| S:76 E:80 ||| CC
3-Hydroxybenzoic  ||| S:80 E:97 ||| NNP
Acid  ||| S:97 E:102 ||| NNP
Pharmaceutical  ||| S:102 E:117 ||| NNP
cocrystal  ||| S:117 E:127 ||| NN
can  ||| S:127 E:131 ||| MD
improve  ||| S:131 E:139 ||| VB
physical  ||| S:139 E:148 ||| JJ
and  ||| S:148 E:152 ||| CC
chemical  ||| S:152 E:161 ||| JJ
properties  ||| S:161 E:172 ||| NNS
of  ||| S:172 E:175 ||| IN
active  ||| S:175 E:182 ||| JJ
pharmaceutical  ||| S:182 E:197 ||| JJ
ingredient  ||| S:197 E:208 ||| NN
( ||| S:208 E:209 ||| -LRB-
API ||| S:209 E:212 ||| NNP
) ||| S:212 E:213 ||| -RRB-
,  ||| S:213 E:215 ||| ,
meanwhile  ||| S:215 E:225 ||| RB
this  ||| S:225 E:230 ||| DT
feature  ||| S:230 E:238 ||| NN
has  ||| S:238 E:242 ||| VBZ
shown  ||| S:242 E:248 ||| VBN
great  ||| S:248 E:254 ||| JJ
potential  ||| S:254 E:264 ||| NN
in  ||| S:264 E:267 ||| IN
improving  ||| S:267 E:277 ||| VBG
the  ||| S:277 E:281 ||| DT
pharmaceutical ||| S:281 E:295 ||| NN
's  ||| S:295 E:298 ||| POS
properties  ||| S:298 E:309 ||| NNS
and  ||| S:309 E:313 ||| CC
characteristics ||| S:313 E:328 ||| NNS
.  ||| S:328 E:330 ||| .
In  ||| S:330 E:333 ||| IN
this  ||| S:333 E:338 ||| DT
study ||| S:338 E:343 ||| NN
,  ||| S:343 E:345 ||| ,
cocrystal  ||| S:345 E:355 ||| JJ
formation  ||| S:355 E:365 ||| NN
between  ||| S:365 E:373 ||| IN
piracetam  ||| S:373 E:383 ||| NN
and  ||| S:383 E:387 ||| CC
3-hydroxybenzoic  ||| S:387 E:404 ||| CD
acid  ||| S:404 E:409 ||| NN
( ||| S:409 E:410 ||| -LRB-
3HBA ||| S:410 E:414 ||| NNP
)  ||| S:414 E:416 ||| -RRB-
using  ||| S:416 E:422 ||| VBG
grinding  ||| S:422 E:431 ||| JJ
method  ||| S:431 E:438 ||| NN
has  ||| S:438 E:442 ||| VBZ
been  ||| S:442 E:447 ||| VBN
characterized  ||| S:447 E:461 ||| VBN
by  ||| S:461 E:464 ||| IN
Fourier  ||| S:464 E:472 ||| NNP
transform  ||| S:472 E:482 ||| FW
infrared  ||| S:482 E:491 ||| FW
( ||| S:491 E:492 ||| -LRB-
FTIR ||| S:492 E:496 ||| NNP
) ||| S:496 E:497 ||| -RRB-
,  ||| S:497 E:499 ||| ,
Raman  ||| S:499 E:505 ||| NNP
and  ||| S:505 E:509 ||| CC
terahertz  ||| S:509 E:519 ||| NNS
( ||| S:519 E:520 ||| -LRB-
THz ||| S:520 E:523 ||| NNP
)  ||| S:523 E:525 ||| -RRB-
spectroscopical  ||| S:525 E:541 ||| JJ
techniques ||| S:541 E:551 ||| NNS
.  ||| S:551 E:553 ||| .
The  ||| S:553 E:557 ||| DT
vibrational  ||| S:557 E:569 ||| JJ
modes  ||| S:569 E:575 ||| NNS
of  ||| S:575 E:578 ||| IN
different  ||| S:578 E:588 ||| JJ
motions  ||| S:588 E:596 ||| NNS
are  ||| S:596 E:600 ||| VBP
obtained  ||| S:600 E:609 ||| VBN
by  ||| S:609 E:612 ||| IN
the  ||| S:612 E:616 ||| DT
assignment  ||| S:616 E:627 ||| NN
of  ||| S:627 E:630 ||| IN
the  ||| S:630 E:634 ||| DT
peaks  ||| S:634 E:640 ||| NNS
in  ||| S:640 E:643 ||| IN
the  ||| S:643 E:647 ||| DT
spectra  ||| S:647 E:655 ||| NN
of  ||| S:655 E:658 ||| IN
the  ||| S:658 E:662 ||| DT
starting  ||| S:662 E:671 ||| VBG
materials  ||| S:671 E:681 ||| NNS
and  ||| S:681 E:685 ||| CC
the  ||| S:685 E:689 ||| DT
cocrystal  ||| S:689 E:699 ||| JJ
components ||| S:699 E:709 ||| NNS
.  ||| S:709 E:711 ||| .
FTIR ||| S:711 E:715 ||| NNP
,  ||| S:715 E:717 ||| ,
Raman  ||| S:717 E:723 ||| NNP
and  ||| S:723 E:727 ||| CC
THz  ||| S:727 E:731 ||| JJ
spectroscopical  ||| S:731 E:747 ||| JJ
results  ||| S:747 E:755 ||| NNS
show  ||| S:755 E:760 ||| VBP
that  ||| S:760 E:765 ||| IN
the  ||| S:765 E:769 ||| DT
vibrational  ||| S:769 E:781 ||| JJ
modes  ||| S:781 E:787 ||| NNS
of  ||| S:787 E:790 ||| IN
the  ||| S:790 E:794 ||| DT
cocrystal  ||| S:794 E:804 ||| NNS
are  ||| S:804 E:808 ||| VBP
different  ||| S:808 E:818 ||| JJ
from  ||| S:818 E:823 ||| IN
those  ||| S:823 E:829 ||| DT
of  ||| S:829 E:832 ||| IN
the  ||| S:832 E:836 ||| DT
starting  ||| S:836 E:845 ||| VBG
materials ||| S:845 E:854 ||| NNS
.  ||| S:854 E:856 ||| .
In  ||| S:856 E:859 ||| IN
addition ||| S:859 E:867 ||| NN
,  ||| S:867 E:869 ||| ,
the  ||| S:869 E:873 ||| DT
dynamic  ||| S:873 E:881 ||| JJ
process  ||| S:881 E:889 ||| NN
of  ||| S:889 E:892 ||| IN
the  ||| S:892 E:896 ||| DT
above  ||| S:896 E:902 ||| JJ
cocrystal  ||| S:902 E:912 ||| JJ
formation  ||| S:912 E:922 ||| NN
is  ||| S:922 E:925 ||| VBZ
investigated  ||| S:925 E:938 ||| VBN
in-depth  ||| S:938 E:947 ||| JJ
with  ||| S:947 E:952 ||| IN
Raman  ||| S:952 E:958 ||| NNP
and  ||| S:958 E:962 ||| CC
THz  ||| S:962 E:966 ||| JJ
spec-  ||| S:966 E:972 ||| JJ
tra ||| S:972 E:975 ||| NN
.  ||| S:975 E:977 ||| .
Piracetam-3HBA  ||| S:977 E:992 ||| NNP
cocrystal  ||| S:992 E:1002 ||| NN
is  ||| S:1002 E:1005 ||| VBZ
formed  ||| S:1005 E:1012 ||| VBN
pretty  ||| S:1012 E:1019 ||| RB
fast  ||| S:1019 E:1024 ||| RB
in  ||| S:1024 E:1027 ||| IN
first  ||| S:1027 E:1033 ||| JJ
several  ||| S:1033 E:1041 ||| JJ
minutes ||| S:1041 E:1048 ||| NNS
,  ||| S:1048 E:1050 ||| ,
and  ||| S:1050 E:1054 ||| CC
then  ||| S:1054 E:1059 ||| RB
the  ||| S:1059 E:1063 ||| DT
formation  ||| S:1063 E:1073 ||| NN
rate  ||| S:1073 E:1078 ||| NN
becomes  ||| S:1078 E:1086 ||| VBZ
slow ||| S:1086 E:1090 ||| JJ
.  ||| S:1090 E:1092 ||| .
After  ||| S:1092 E:1098 ||| IN
35  ||| S:1098 E:1101 ||| CD
minutes ||| S:1101 E:1108 ||| NNS
,  ||| S:1108 E:1110 ||| ,
such  ||| S:1110 E:1115 ||| JJ
formation  ||| S:1115 E:1125 ||| NN
process  ||| S:1125 E:1133 ||| NN
has  ||| S:1133 E:1137 ||| VBZ
been  ||| S:1137 E:1142 ||| VBN
completed ||| S:1142 E:1151 ||| VBN
.  ||| S:1151 E:1153 ||| .
The  ||| S:1153 E:1157 ||| DT
results  ||| S:1157 E:1165 ||| NNS
offer  ||| S:1165 E:1171 ||| VBP
the  ||| S:1171 E:1175 ||| DT
theoretical  ||| S:1175 E:1187 ||| JJ
benchmark  ||| S:1187 E:1197 ||| NN
and  ||| S:1197 E:1201 ||| CC
unique  ||| S:1201 E:1208 ||| JJ
means  ||| S:1208 E:1214 ||| NNS
for  ||| S:1214 E:1218 ||| IN
real-time  ||| S:1218 E:1228 ||| JJ
monitoring  ||| S:1228 E:1239 ||| NN
pharmaceutical  ||| S:1239 E:1254 ||| JJ
cocrystal  ||| S:1254 E:1264 ||| JJ
formation  ||| S:1264 E:1274 ||| NN
and  ||| S:1274 E:1278 ||| CC
also  ||| S:1278 E:1283 ||| RB
the  ||| S:1283 E:1287 ||| DT
corresponding  ||| S:1287 E:1301 ||| JJ
quantitative  ||| S:1301 E:1314 ||| JJ
analysis  ||| S:1314 E:1323 ||| NN
in  ||| S:1323 E:1326 ||| IN
the  ||| S:1326 E:1330 ||| DT
pharmaceutical  ||| S:1330 E:1345 ||| JJ
field ||| S:1345 E:1350 ||| NN
.  ||| S:1350 E:1352 ||| .
